Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupPlasma cell neoplasmsDiseaseTEMPI SyndromeSubgroupICD10D75.1MeSHSequenceDRTM1800, TEMPI syndrome, C1-2 (PID2167) -|- C3-6 (PID2168) -|- C7+ (PID2169)ChemotherapyChemo-substanceBortezomibDaratumumabChemo-substanceBortezomibDaratumumabChemo-substanceBortezomibDaratumumabChemo-substanceBortezomibDaratumumabNo. Substances1 RadiotherapySupportive therapySupportive substanceAciclovirDimetindenGranisetronMontelukastParacetamolPrednisoloneSupportive substanceAciclovirDimetindenGranisetronMontelukastParacetamolPrednisoloneSupportive substanceAciclovirDimetindenGranisetronMontelukastParacetamolPrednisoloneSupportive substanceAciclovirDimetindenGranisetronMontelukastParacetamolPrednisoloneNo. Substances25Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlCardiotoxicityEmetogenicity (MASCC/ESMO)FatigueGastrointestinal ToxicityHerpes ZosterHypertensionInfectionsInfusion ReactionNauseaNeuropathyNeutropeniaPainPneumoniaRashThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorKwok MSykes DBDiseaseTEMPI-SyndromOriginMassachusetts General Hospital, BostonNational Cancer Institute BethesdaProtocols in Revision 4 protocols foundProtocols under revision.Bortezomib 1,3, TEMPI syndrome (PID2182 V1.0)Daratumumab 1800, TEMPI syndrome, cycle 1-2 (PID2167 V1.0)Daratumumab 1800, TEMPI syndrome, cycle 3-6 (PID2168 V1.0)Daratumumab 1800, TEMPI syndrome, cycle 7+ (PID2169 V1.0)
